Securities code: 688289 securities abbreviation: Sansure Biotech Inc(688289) Announcement No.: 2022-001 Sansure Biotech Inc(688289)
Announcement on the progress of share repurchase through centralized bidding transaction
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
1、 Basic information of share repurchase
Sansure Biotech Inc(688289) (hereinafter referred to as “the company”) convened the eighth extraordinary meeting of the first board of directors in 2021 on October 21, 2021, deliberated and adopted the proposal on repurchase of shares of the company by means of centralized bidding transaction, and agreed that the company would repurchase shares of the company by means of centralized bidding transaction, with a total repurchase fund of no less than RMB 200 million (including), It shall not exceed RMB 260 million (inclusive), the repurchase price shall not exceed RMB 70 / share (inclusive), and the repurchase period shall be within 6 months from the date when the board of directors of the company deliberates and approves the repurchase plan. For details, please refer to the company’s disclosure on the website of Shanghai Stock Exchange (www.sse. Com.. CN.) on October 22, 2021 and November 3, 2021 Announcement of Sansure Biotech Inc(688289) on repurchase of shares of the company through centralized bidding transaction (Announcement No.: 2021-062) and report of Sansure Biotech Inc(688289) on repurchase of shares through centralized bidding transaction (Announcement No.: 2021-073). After the implementation of the company’s quarterly equity distribution in 2021, the upper limit of the company’s share repurchase price in the form of centralized bidding transaction is adjusted from no more than 70.00 yuan / share (inclusive) to no more than 69.25 yuan / share (inclusive). For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com.. CN.) on December 4, 2021 A notice on the adjustment of the price cap of repurchase shares after the implementation of quarterly equity allocation in 2021 (Announcement No.: 2021-091) is disclosed.
2、 Progress of share repurchase
According to the relevant provisions of the detailed rules for the implementation of share repurchase by listed companies of Shanghai Stock Exchange, during the period of share repurchase, the company shall announce the progress of share repurchase as of the end of last month within the first three trading days of each month. The progress of the company’s repurchase is hereby announced as follows:
During the period from December 1, 2021 to December 31, 2021, the company has repurchased 2687950 shares through the trading system of Shanghai stock exchange through centralized bidding, accounting for 0.67% of the company’s total share capital of 40000000 shares. The highest price of repurchase is 58.96 yuan / share and the lowest price is 53.071 yuan / share, The total amount of funds paid is RMB 150088748.63 (excluding stamp duty, transaction commission and other transaction expenses). As of December 31, 2021, the company has repurchased 3607950 shares through centralized bidding trading through the trading system of Shanghai Stock Exchange, accounting for 0.90% of the company’s total share capital of 40000000 shares. The highest price of repurchase transaction is 58.96 yuan / share and the lowest price is 53.071 yuan / share, The total amount of funds paid is RMB 199983820.97 (excluding stamp duty, transaction commission and other transaction expenses).
The above repurchased shares comply with the provisions of relevant laws and regulations and the company’s share repurchase plan.
3、 Other matters
In strict accordance with the detailed rules for the implementation of share repurchase by listed companies of Shanghai Stock Exchange and the company’s share repurchase plan, the company will make and implement the repurchase decision according to the market conditions during the repurchase period, and timely perform the obligation of information disclosure according to the progress of share repurchase. Please pay attention to the investment risk.
It is hereby announced.
Sansure Biotech Inc(688289) board of directors January 4, 2022
